The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results, Practical Considerations for Personalized Cancer Care

Molecular Tumor Board: 47-year-old male with papillary thyroid cancer and BRAF V600E alteration

Molecular Tumor Board case for discussion: 47-year-old male with papillary thyroid cancer, harboring a BRAF V600E alteration. We discuss the diagnosis and risk stratification, including the role of fine needle aspiration and cytology to assess thyroid nodules. We also review management including surgery and the importance of lifelong thyroid replacement. Learn about the clinical journey of this rare cancer, with insights into genetic mutations, histologic features, and treatment strategies.

Molecular Tumor Board: 82-year-old female with high grade ovarian serous adenocarcinoma and BRCA1 F709fs mutation

An 82-year-old with advanced high-grade serous ovarian cancer and a BRCA1 mutation highlights the importance of somatic and germline testing to guide therapy and using PARP inhibitors for maintenance. Join our Molecular Tumor Board to explore treatment strategies and the impact of reversion mutations on resistance management.

Labcorp Perspectives: Optimizing biomarker testing in advanced NSCLC: Insights on comprehensive genomic profiling (CGP)

In the latest episode of Labcorp Perspectives: Oncology, Dr. Rebecca Ann Previs and Dr. Kyle Strickland, directors of medical affairs at Labcorp Oncology, delve into the significant advantages of comprehensive genomic profiling (CGP) over single-gene testing in patients with advanced non-small cell lung cancer (NSCLC). This study, using OmniSeq® INSIGHT, showed that CGP enables that patients with NSCLC to be tested for all recommended biomarkers at once, providing the best chance of identifying effective treatment options.

Molecular Tumor Board: 75-year-old male presents with a several month history of a painful tongue lesion and weight loss

In this Molecular Tumor Board we review cases of oral cavity squamous cell carcinoma and explore the clinical utility of lymphatic fluid collected from surgical drains as a novel source of ctDNA. This innovative approach from Droplet Biosciences offers potential for more precision monitoring and personalized treatment strategies. 

Presented by:

Wendy Winckler, PhD
Chief Science Officer
Droplet Biosciences

Jose Zevallos, MD, MPH
Scientific Co-founder
Droplet Biosciences

Labcorp Perspectives: Oncology | Innovations in oncology: Highlights from ASCO's annual meeting (Episode 3)

The latest episode of Labcorp Perspectives: Oncology featuring Dr. Rebecca Previs, director of medical affairs at Labcorp Oncology, and Dr. Eric Severson, executive director of medical affairs at Labcorp, share notable insights from the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. They explore the role of liquid biopsies in cancer diagnostics, specifically Labcorp's Plasma Complete™ test, a noninvasive alternative to traditional biopsies.

Biomarkers of Immunotherapy Response: Current State-of-the-Art and Emerging Trends

Molecular Tumor Board: 56-year-old with endometrial cancer and POLE V411L alteration

Uterine cancer is the most common gynecologic cancer in the US, with increasing incidence and mortality rate. This Molecular Tumor Board case presented is about a 56-year-old female patient with uterine cancer and an underlying POLE V411L alteration. Join us as we discuss molecular subgroups in uterine cancer and how molecular classification impacts targeted therapy options.

ACMG 2024: From screening to diagnostic solutions: Comprehensive testing for women's health and wellness

Molecular Tumor Board: 52-year-old male with colon cancer and POLE P286R alteration

Did you know that a subset of patients with microsatellite-stable (MSS) colon cancer have POLE/POLD1 mutations that are associated with high clinical response to immunotherapy?

Join us for this molecular tumor board where we reviewed a case of metastatic MSS-colon cancer with a POLE mutation and high tumor mutational burden, detected on a comprehensive genomic and immune profiling (CGIP) platform. We discuss the incidence and therapeutic significance of POLE/POLD1 proofreading deficiency mutations in patients with colon cancer.